P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970508.43614.c0 |
| _version_ | 1827332345644974080 |
|---|---|
| author | Evangelos Terpos Maria Gavriatopoulou Eirini Katodritou Evdoxia Hatjiharissi Ioanna Dialoupi Evgenia Verrou Kyriaki Manousou Stavros Gkolfinopoulos Magdalini Migkou Sosana Delimpasi Argiris Symeonidis Efstathios Kastritis Meletios A. Dimopoulos |
| author_facet | Evangelos Terpos Maria Gavriatopoulou Eirini Katodritou Evdoxia Hatjiharissi Ioanna Dialoupi Evgenia Verrou Kyriaki Manousou Stavros Gkolfinopoulos Magdalini Migkou Sosana Delimpasi Argiris Symeonidis Efstathios Kastritis Meletios A. Dimopoulos |
| author_sort | Evangelos Terpos |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:58:38Z |
| format | Article |
| id | doaj.art-0757b59f59da40e7b1d70bb3e4fe150c |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:58:38Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-0757b59f59da40e7b1d70bb3e4fe150c2024-03-03T03:26:13ZengWileyHemaSphere2572-92412023-08-017e43614c010.1097/01.HS9.0000970508.43614.c0202308003-00801P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDYEvangelos Terpos0Maria Gavriatopoulou1Eirini Katodritou2Evdoxia Hatjiharissi3Ioanna Dialoupi4Evgenia Verrou5Kyriaki Manousou6Stavros Gkolfinopoulos7Magdalini Migkou8Sosana Delimpasi9Argiris Symeonidis10Efstathios Kastritis11Meletios A. Dimopoulos121 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece2 Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece3 First Department of Internal Medicine, Division of Haematology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece2 Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece4 Health Data Specialists, Dublin, Ireland4 Health Data Specialists, Dublin, Ireland1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece5 Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece6 Hematology Division, Dept. of Internal Medicine, University of Patras Medical School, Patras, Greece1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greecehttp://journals.lww.com/10.1097/01.HS9.0000970508.43614.c0 |
| spellingShingle | Evangelos Terpos Maria Gavriatopoulou Eirini Katodritou Evdoxia Hatjiharissi Ioanna Dialoupi Evgenia Verrou Kyriaki Manousou Stavros Gkolfinopoulos Magdalini Migkou Sosana Delimpasi Argiris Symeonidis Efstathios Kastritis Meletios A. Dimopoulos P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY HemaSphere |
| title | P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY |
| title_full | P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY |
| title_fullStr | P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY |
| title_full_unstemmed | P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY |
| title_short | P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY |
| title_sort | p901 daratumumab ixazomib and dexamethasone in patients with relapsed refractory multiple myeloma pre treated with a lenalidomide based regimen final outcomes of the phase 2 daria study |
| url | http://journals.lww.com/10.1097/01.HS9.0000970508.43614.c0 |
| work_keys_str_mv | AT evangelosterpos p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT mariagavriatopoulou p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT eirinikatodritou p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT evdoxiahatjiharissi p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT ioannadialoupi p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT evgeniaverrou p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT kyriakimanousou p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT stavrosgkolfinopoulos p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT magdalinimigkou p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT sosanadelimpasi p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT argirissymeonidis p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT efstathioskastritis p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy AT meletiosadimopoulos p901daratumumabixazomibanddexamethasoneinpatientswithrelapsedrefractorymultiplemyelomapretreatedwithalenalidomidebasedregimenfinaloutcomesofthephase2dariastudy |